GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » E10

Innovation Pharmaceuticals (Innovation Pharmaceuticals) E10 : $-0.09 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Innovation Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was $-0.002. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.09 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average E10 Growth Rate was -4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Innovation Pharmaceuticals was -4.00% per year. The lowest was -14.50% per year. And the median was -9.25% per year.

As of today (2024-04-28), Innovation Pharmaceuticals's current stock price is $0.003. Innovation Pharmaceuticals's E10 for the quarter that ended in Sep. 2023 was $-0.09. Innovation Pharmaceuticals's Shiller PE Ratio of today is .


Innovation Pharmaceuticals E10 Historical Data

The historical data trend for Innovation Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation Pharmaceuticals E10 Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.08 -0.09 - -0.09

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.09 -0.09 -0.09 -0.09

Competitive Comparison of Innovation Pharmaceuticals's E10

For the Biotechnology subindustry, Innovation Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Shiller PE Ratio falls into.



Innovation Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Innovation Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.002/129.8595*129.8595
=-0.002

Current CPI (Sep. 2023) = 129.8595.

Innovation Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201312 -0.030 98.326 -0.040
201403 -0.020 99.695 -0.026
201406 -0.030 100.560 -0.039
201409 -0.040 100.428 -0.052
201412 -0.020 99.070 -0.026
201503 -0.020 99.621 -0.026
201506 -0.020 100.684 -0.026
201509 -0.020 100.392 -0.026
201512 -0.030 99.792 -0.039
201603 -0.030 100.470 -0.039
201606 -0.030 101.688 -0.038
201609 -0.020 101.861 -0.025
201612 -0.030 101.863 -0.038
201703 -0.030 102.862 -0.038
201706 -0.040 103.349 -0.050
201709 -0.030 104.136 -0.037
201712 -0.030 104.011 -0.037
201803 -0.020 105.290 -0.025
201806 -0.030 106.317 -0.037
201809 -0.010 106.507 -0.012
201812 -0.020 105.998 -0.025
201903 -0.010 107.251 -0.012
201906 -0.010 108.070 -0.012
201909 -0.010 108.329 -0.012
201912 -0.010 108.420 -0.012
202003 -0.004 108.902 -0.005
202006 -0.010 108.767 -0.012
202009 -0.003 109.815 -0.004
202012 -0.020 109.897 -0.024
202103 -0.010 111.754 -0.012
202106 -0.010 114.631 -0.011
202109 -0.005 115.734 -0.006
202112 -0.004 117.630 -0.004
202203 -0.003 121.301 -0.003
202206 0.000 125.017 0.000
202209 -0.003 125.227 -0.003
202212 -0.001 125.222 -0.001
202303 -0.001 127.348 -0.001
202306 -0.005 128.729 -0.005
202309 -0.002 129.860 -0.002

Add all the adjusted EPS together and divide 10 will get our e10.


Innovation Pharmaceuticals  (OTCPK:IPIX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Innovation Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Innovation Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
Executives
Arthur Peter Bertolino officer: Pres. & Chief Medical Officer C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness officer: Vice President 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin director C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor director 17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter director 7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich director, 10 percent owner, officer: Chief Financial Officer C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon director, 10 percent owner, officer: President-Chief Scient.Officer 10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans director, officer: Chief Executive Officer 17 IRVING PLACE, PELHAM NY 10803

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Headlines

From GuruFocus